Renal organic anion transport systems play an important role in the excretion of anionic drugs and toxic compounds. Probenecid has been used as a potent inhibitor of urinary and biliary excretion of anionic compounds mediated by transporters such as organic anion transporters and multidrug resistance-associated protein 2 (Mrp2). The purpose of this study was to optimize the dose of probenecid required for selective inhibition of urinary excretion of anionic compounds in rats, without inhibition of biliary excretion. Phenolsulfonphthalein (PSP), a model anionic compound that is excreted in urine and bile, was intravenously administered to rats after intraperitoneal injection of different doses of probenecid (0, 0.2, 2, 10, 100, 200 and 400 mg kg(-1) ). Treatment with 100, 200 or 400 mg kg(-1) probenecid decreased both renal clearance (CLr ) and biliary clearance (CLb ) of PSP, whereas 0.2 mg kg(-1) probenecid did not have any effect. Probenecid administered at doses of 2 and 10 mg kg(-1) decreased only CLr . The median effective doses of probenecid for inhibiting CLr and CLb were 0.925 and 23.9 mg kg(-1) , respectively. These data suggest that a low dose of probenecid selectively inhibits urinary excretion of PSP that may be mediated by organic anion transporters, without affecting biliary excretion that may be mediated by Mrp2.

In this study, we investigated pharmacokinetic drug interactions of clopidogrel with P-gp inhibitors in rats and dogs. Following the oral administration of clopidogrel with or without the P-gp inhibitors, quercetin (250 mg/kg), telmisartan (8 mg/kg), and cyclosporine A (10 mg/kg), in rats and dogs, the plasma concentration-time profiles of clopidogrel carboxylic acid, a surrogate marker for the bioavailability of clopidogrel, were determined. Co-administration of the quercetin, telmisartan and cyclosporine A significantly increased the area under the curve and peak plasma concentration of clopidogrel carboxylic acid in rats. However, in dogs, the plasma concentrations of clopidogrel carboxylic acid were not considerably changed by the coadministration of three different kinds of P-gp inhibitors. These findings suggest potential interaction of clopidogrel with quercetin, telmisartan, and cyclosporine A, although there are differences between animal models. Follow-up clinical study is needed to explore the meaning of this remarkable species differences in the P-gp-mediated interaction.

No abstract

No abstract

No abstract